Regeneron Pharmaceuticals, Inc.
REGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000872589
In the last 90 days, Regeneron Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 1,341 institutions reported holding it in 13F filings for Q2 2026, worth $57.1B in total; Southeastern Asset Management (Longleaf) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.43M in total
- 5
- 13F holdersQ2 2026, −44 vs. previous quarter
- 1,341
- 13F valueReported value at the end of Q2 2026
- $57.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding REGN, Q2 2026
1 superinvestor reports holding Regeneron Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Southeastern Asset Management (Longleaf)
Mason Hawkins
5.0%
Regeneron Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 152,322
- Value
- $95.0M
Latest insider trades
Open-market purchases and sales by Regeneron Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:50 PM ET | Sep 2-3 | 1 day | McCourt MarionEVP Commercial | SSale | −2.35K | $853.56 | −$2.00M | −16.3%12.0K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:47 PM ET | Sep 2 | 1 day | Guarini KathrynDirector | SSale | −400 | $850.00 | −$340.0K | −39.9%603 after | 10b5-1 |
| Aug 12, 2026 (view filing)4:16 PM ET | Aug 10 | 2 days | Guarini KathrynDirector | SSale | −400 | $800.00 | −$320.0K | −39.9%603 after | 10b5-1 |
| Aug 12, 2026 (view filing)4:14 PM ET | Aug 10 | 2 days | Zoghbi Huda YDirector | SSale | −800 | $800.00 | −$640.0K | −32.0%1.70K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:05 PM ET | Jul 2 | 5 days | Ryan Arthur FDirector | SSale | −200 | $650.15 | −$130.0K | −1.1%17.3K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Ryan Arthur FDirector | SSale | −100 | $705.24 | −$70.5K | −0.6%17.5K after | 12 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Ryan Arthur FDirector | SSale | −100 | $777.27 | −$77.7K | −0.6%17.6K after | 9 lots10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Ryan Arthur FDirector | SSale | −100 | $785.50 | −$78.5K | −0.6%17.7K after | 13 lots10b5-1 |
| Feb 23, 2026 (view filing) | Feb 19 | 4 days | Zoghbi Huda YDirector | SSale | −1.64K | $781.33 | −$1.28M | −49.0%1.70K after | 11 lots10b5-1 |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Pitofsky JasonSVP Controller | SSale | −2.04K | $778.52 | −$1.59M | −32.3%4.27K after | 11 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Regeneron Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,113,506 | $5.68B | 0.08% | +165,771+1.9% | Added |
| Vanguard Capital Management LLC | 6,629,759 | $4.13B | 0.09% | −25,154−0.4% | Reduced |
| Dodge & Cox | 4,871,137 | $3.04B | 1.59% | +412,899+9.3% | Added |
| State Street Corp | 4,834,688 | $3.01B | 0.09% | +170,210+3.6% | Added |
| Invesco Ltd. | 3,940,665 | $2.46B | 0.19% | +35,556+0.9% | Added |
| JPMorgan Chase & Co | 3,774,199 | $2.38B | 0.14% | −537,607−12.5% | Reduced |
| Vanguard Portfolio Management LLC | 3,175,313 | $1.98B | 0.09% | +1,454,539+84.5% | Added |
| Franklin Resources Inc | 2,771,839 | $1.73B | 0.37% | +49,768+1.8% | Added |
| Geode Capital Management, LLC | 2,625,810 | $1.63B | 0.09% | +18,078+0.7% | Added |
| Nuveen, LLC | 2,019,974 | $1.26B | 0.30% | −45,090−2.2% | Reduced |